Brain structural effects of antipsychotic treatment in schizophrenia: A systematic review

Current Neuropharmacology

Volumn 13, Issue 4, 2015, Pages 422-434

  Roiz Santiañez, Roberto ^a,b   Suarez Pinilla, Paula ^a,b   Crespo Facorro, Benedicto ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotic; Longitudinal studies; Schizophrenia; Structural magnetic resonance imaging

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE BESYLATE; MOLINDONE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL; NEUROLEPTIC AGENT;

BRAIN MALFORMATION; BRAIN SIZE; CAUDATE NUCLEUS; CORTICAL THICKNESS (BRAIN); HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SURFACE AREA; SYSTEMATIC REVIEW; VOXEL BASED MORPHOMETRY; ANIMAL; BRAIN; DRUG EFFECTS; LONGITUDINAL STUDY; NEUROIMAGING; PATHOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; SCHIZOPHRENIA;

EID: 84942119593     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13666150429002536     Document Type: Review

References (79)

1. Haijma, S. V.; Van Haren, N.; Cahn W.; Koolschijn, P. C.; Hulshoff Pol, H. E.; Kahn R. S. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr. Bull., 2013, 39(5), 1129-38. http://dx.doi.org/10.1093/schbul/sbs118
2. Steen, R. G.; Mull, C.; McClure, R.; Hamer, R. M.; Lieberman J. A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry, 2006, 188, 510-8. http://dx.doi.org/10.1192/bjp.188. 6.510
3. Vita, A.; De Peri, L.; Silenzi, C.; Dieci, M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr. Res., 2006, 82(1), 75-88. http://dx.doi.org/10.1016/j.schres.2005.11.004
4. Olabi, B.; Ellison-Wright, I.; McIntosh, A. M.; Wood, S. J.; Bullmore, E.; Lawrie, S. M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol. Psychiatry, 2011, 70(1), 88-96. http://dx. doi.org/10.1016/j.biopsych.2011.01.032
5. Molina, V.; Reig, S.; Sanz, J.; Palomo, T.; Benito, C.; Sanchez, J.; Sarramea, F.; Pascau, J.; Desco, M. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr. Res., 2005, 80(1), 61-71. http://dx.doi.org/10.1016/j.schres.2005.07.031
6. Lieberman, J. A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry, 1999, 46(6), 729-39. http://dx.doi.org/10.1016/S0006-3223(99)00147-X
7. Ho, B. C.; Andreasen, N. C.; Ziebell, S.; Pierson, R.; Magnotta,V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry, 2011, 68(2), 128-37. http://dx.doi.org/10.1001/ archgenpsychiatry.2010.199
8. Weinberger, D. R.; McClure, R. K. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch. Gen. Psychiatry, 2002, 59(6), 553-8. http://dx.doi.org/10.1001/archpsyc.59.6.553
9. Sporn, A. L.; Greenstein, D. K.; Gogtay, N.; Jeffries, N. O.; Lenane, M.; Gochman, P.; Clasen, L. S.; Blumenthal, J.; Giedd, J. N.; Rapoport J. L. Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am. J. Psychiatry, 2003, 160(12), 2181-9. http://dx.doi.org/10.1176/appi.ajp.160.12. 2181
10. Hastings, T. G.; Lewis, D. A.; Zigmond M. J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(5), 1956-61. http://dx.doi.org/10. 1073/pnas.93.5.1956
11. Ho, B. C.; Andreasen, N. C.; Nopoulos, P.; Arndt, S.; Magnotta, V.; Flaum, M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry, 2003, 60(6), 585-94. http://dx.doi.org/10.1001/archpsyc.60.6.585
12. Prabakaran, S.; Swatton, J. E.; Ryan, M. M.; Huffaker, S. J.; Huang, J. T.; Griffin, J. L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K. S.; Karp, N. A.; Hester, S.; Tkachev, D.; Mimmack, M. L.; Yolken, R. H.; Webster, M. J.; Torrey, E. F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry, 2004, 9(7), 684-97, 43. http://dx.doi.org/10.1016/ j.pscychresns.2011.10.001
13. Roiz-Santianez, R.; Perez-Iglesias, R.; Ortiz-Garcia de la Foz, V.; Tordesillas-Gutierrez, D.; Mata, I.; Gonzalez-Mandly, A.; Pazos, A.; Tabares-Seisdedos, R.; Vazquez-Barquero, J. L.; Crespo-Facorro, B. One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients. Psychiatry Res., 2012, 202(1), 80-3. http://dx.doi.org/10.1038/ sj.npp.1300710
14. Dorph-Petersen, K. A.; Pierri, J. N.; Perel, J. M.; Sun, Z.; Sampson A. R.; Lewis, D. A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology, 2005, 30(9), 1649-61. http://dx.doi.org/10.1038/sj.npp.1300710
15. Takahashi, T.; Wood, S. J.; Soulsby, B.; McGorry, P. D.; Tanino, R.; Suzuki, M.; Velakoulis, D.; Pantelis, C. Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophr. Res., 2009, 108(1-3), 49-56. http://dx. doi.org/10.1016/j.schres.2008.12.029
16. Navari, S.; Dazzan, P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med., 2009, 39(11), 1763-77. http://dx.doi.org/10.1017/ S0033291709005315
17. Cobia D. J.; Smith M. J.; Wang L.; Csernansky J. G. Longitudinal progression of frontal and temporal lobe changes in schizophrenia. Schizophr. Res., 2012, 139(1-3), 1-6. http://dx.doi.org/10.1016/j. schres.2012.05.002
18. Newton S. S.; Duman R. S. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs, 2007, 21(9), 715-25. http://dx.doi.org/10.2165/00023210-200721090-00002
19. Goghari, V. M.; Smith, G. N.; Honer, W. G.; Kopala, L. C.; Thornton, A. E.; Su, W.; Macewan, G. W.; Lang D. J. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naive first-episode psychosis patients. Schizophr. Res., 2013, 149(1-3), 149-55. http://dx.doi.org/10.1016/j.schres. 2013.06.025
20. van Haren N. E.; Cahn W.; Hulshoff Pol H. E.; Kahn, R. S. The course of brain abnormalities in schizophrenia: can we slow the progression? J. Psychopharmacol., 2012, 26(5 Suppl), 8-14. http://dx.doi.org/10.1177/0269881111408964
21. van Haren, N. E.; Schnack, H. G.; Cahn, W.; van den Heuvel, M. P.; Lepage, C.; Collins, L.; Evans, A. C.; Hulshoff Pol, H. E.; Kahn, R. S. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry, 2011, 68(9), 871-80. http://dx.doi.org/10.1001/archgenpsychiatry.2011.88
22. Konradi, C.; Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry, 2001, 50(10), 729-42. http://dx.doi.org/10.1016/S0006-3223(01)01267-7
23. Tauscher-Wisniewski, S.; Tauscher, J.; Christensen, B. K.; Mikulis, D. J.; Zipursky, R. B. Volumetric MRI measurement of caudate nuclei in antipsychotic-naive patients suffering from a first episode of psychosis. J. Psychiatr. Res., 2005, 39(4), 365-70. http://dx.doi.org/10.1016/j.jpsychires.2004.10.001
24. Pillai, A.; Parikh, V.; Terry, A. V., Jr.; Mahadik, S. P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res., 2007, 41(5), 372-86. http://dx.doi.org/10.1016/ j.jpsychires.2006.01.011
25. Tauscher-Wisniewski, S.; Tauscher, J.; Logan, J.; Christensen, B. K.; Mikulis, D. J.; Zipursky, R. B. Caudate volume changes in first episode psychosis parallel the effects of normal aging: a 5-year follow-up study. Schizophr. Res., 2002, 58(2-3), 185-8. http://dx. doi.org/10.1016/S0920-9964(01)00406-6
26. Parikh, V.; Khan, M. M.; Terry, A.; Mahadik, S. P. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J. Psychiatr. Res., 2004, 38(5), 521-9. http://dx.doi.org/10.1016/j.jpsychires.2004.03.008
27. Chakos, M. H.; Lieberman, J. A.; Bilder, R. M.; Borenstein, M.; Lerner, G.; Bogerts B.; Wu, H.; Kinon, B.; Ashtari, M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry, 1994, 151(10), 1430-6. http://dx.doi.org/10.1176/ajp.151.10.1430
28. Whitwell, J. L.; Josephs, K. A.; Rossor, M. N.; Stevens, J. M.; Revesz, T.; Holton, J. L.; Al-Sarraj, S.; Godbolt, A. K.; Fox N. C.; Warren J. D. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch. Neurol., 2005, 62(9), 1402-8. http://dx.doi.org/10.1001/archneur.62.9.1402
29. Keshavan, M. S.; Bagwell, W. W.; Haas, G. L.; Sweeney, J. A.; Schooler, N. R.; Pettegrew, J. W. Changes in caudate volume with neuroleptic treatment. Lancet, 1994, 344(8934), 1434. http://dx. doi.org/10.1016/S0140-6736(94)90599-1
30. Arango, C.; Rapado-Castro, M.; Reig, S.; Castro-Fornieles, J.; Gonzalez-Pinto, A.; Otero, S.; Baeza, I.; Moreno C.; Graell, M.; Janssen, J.; Parellada, M.; Moreno, D.; Bargallo, N.; Desco, M. Progressive brain changes in children and adolescents with firstepisode psychosis. Arch. Gen. Psychiatry, 2012, 69(1), 16-26. http://dx.doi.org/10.1001/archgenpsychiatry.2011.150
31. Okugawa, G.; Nobuhara, K.; Takase, K.; Saito, Y.; Yoshimura, M.; Kinoshita, T. Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia. Neuropsychobiology, 2007, 55(1), 43-6. http://dx.doi.org/10.1159/ 000103575
32. Reig, S.; Moreno, C.; Moreno, D.; Burdalo, M.; Janssen, J.; Parellada, M.; Zabala, A.; Desco, M.; Arango, C. Progression of brain volume changes in adolescent-onset psychosis. Schizophr. Bull., 2009, 35(1), 233-43. http://dx.doi.org/10.1093/schbul/sbm160
33. Frazier, J. A.; Giedd, J. N.; Kaysen, D.; Albus, K.; Hamburger, S.; Alaghband-Rad, J.; Lenane, M. C.; McKenna, K.; Breier, A.; Rapoport, J. L. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am. J. Psychiatry, 1996, 153(4), 564-6. http://dx.doi.org/10.1176/ajp.153.4.564
34. Nakamura, M.; Salisbury, D. F.; Hirayasu, Y.; Bouix, S.; Pohl, K. M.; Yoshida, T.; Koo, M. S.; Shenton, M. E.; McCarley, R. W. Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biol Psychiatry, 2007, 62(7), 773-83. http://dx.doi.org/ 10.1016/j.biopsych.2007.03.030
35. Taylor, S.; Christensen, J. D.; Holcomb, J. M.; Garver, D. L. Volume increases in striatum associated with positive symptom reduction in schizophrenia: a preliminary observation. Psychiatry Res., 2005, 140(1), 85-9. http://dx.doi.org/10.1016/j.pscychresns. 2005.06.004
36. McClure, R. K.; Carew, K.; Greeter, S.; Maushauer, E.; Steen, G.; Weinberger, D. R. Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment. Schizophr. Res., 2008, 98(1-3), 29-39. http://dx.doi.org/ 10.1016/j.schres.2007.05.012
37. Cahn, W.; Hulshoff Pol, H. E.; Lems, E. B.; van Haren, N. E.; Schnack, H. G.; van der Linden, J. A.; Schothorst, P. F.; van Engeland, H.; Kahn, R. S. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry, 2002, 59(11), 1002-10. http://dx.doi.org/10.1001/archpsyc.59. 11.1002
38. Ebdrup, B. H.; Skimminge, A.; Rasmussen, H.; Aggernaes, B.; Oranje, B.; Lublin, H.; Baare, W.; Glenthoj, B. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, firstepisode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int. J. Neuropsychopharmacol., 2011, 14(1), 69-82. http://dx.doi.org/10.1017/S1461145710000817
39. Gur, R. E.; Cowell, P.; Turetsky, B. I.; Gallacher, F.; Cannon, T.; Bilker, W.; Gur, R. C. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch. Gen. Psychiatry, 1998, 55(2), 145-52. http://dx.doi.org/10.1001/archpsyc.55.2.145
40. Boonstra, G.; van Haren, N. E.; Schnack, H. G.; Cahn, W.; Burger, H.; Boersma, M.; de Kroon, B.; Grobbee, D. E.; Hulshoff Pol H. E.; Kahn R. S. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J. Clin. Psychopharmacol., 2011, 31(2), 146-53. http://dx.doi.org/10.1097/ JCP.0b013e31820e3f58
41. van Haren, N. E.; Hulshoff Pol, H. E.; Schnack, H. G.; Cahn, W.; Brans, R.; Carati, I.; Rais, M.; Kahn R. S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry, 2008, 63(1), 106-13. http://dx.doi.org/10.1016/j.biopsych.2007. 01.004
42. Heitmiller, D. R.; Nopoulos P. C.; Andreasen N. C. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr. Res., 2004, 66(2-3), 137-42. http://dx.doi.org/10.1016/j.schres.2003.08.008
43. Massana, G.; Salgado-Pineda, P.; Junque, C.; Perez, M.; Baeza, I.; Pons A.; Massana J.; Navarro V.; Blanch J.; Morer A.; Mercader J. M.; Bernardo M. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J. Clin. Psychopharmacol., 2005, 25(2), 111-7. http://dx.doi.org/ 10.1097/01.jcp.0000155818.29091.53
44. Roiz-Santianez, R.; Ayesa-Arriola, R.; Tordesillas-Gutierrez, D.; Ortiz-Garcia de la Foz, V.; Perez-Iglesias, R.; Pazos, A.; Sanchez, E.; Crespo-Facorro, B. Three-year longitudinal population-based volumetric MRI study in first-episode schizophrenia spectrum patients. Psychol. Med., 2014, 44(8), 1591-604. http://dx.doi.org/ 10.1017/S0033291713002365
45. Saijo, T.; Abe, T.; Someya, Y.; Sassa, T.; Sudo, Y.; Suhara, T.; Shuno, T.; Asai, K.; Okubo, Y. Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study. Psychiatry Clin. Neurosci., 2001, 55(1), 41-7. http://dx.doi.org/10. 1046/j.1440-1819.2001.00783.x
46. Andersson, C.; Hamer, R. M.; Lawler, C. P.; Mailman, R. B.; Lieberman, J. A. Striatal volume changes in the rat following longterm administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology, 2002, 27(2), 143-51. http://dx.doi. org/10.1016/S0893-133X(02)00287-7
47. Driemeyer, J.; Boyke, J.; Gaser, C.; Buchel, C.; May, A. Changes in gray matter induced by learning--revisited. PLoS One, 2008, 3(7), e2669. http://dx.doi.org/10.1371/journal.pone.0002669
48. Puri, B. K.; Hutton, S. B.; Saeed, N.; Oatridge, A.; Hajnal, J. V.; Duncan, L.; Chapman, M. J.; Barnes, T. R.; Bydder, G. M.; Joyce E. M. A serial longitudinal quantitative MRI study of cerebral changes in first-episode schizophrenia using image segmentation and subvoxel registration. Psychiatry Res., 2001, 106(2), 141-50. http://dx.doi.org/10.1016/S0925-4927(01)00072-5
49. Tost H.; Braus D. F.; Hakimi S.; Ruf M.; Vollmert C.; Hohn F.; Meyer-Lindenberg A. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat. Neurosci, 2010, 13(8), 920-2. http://dx.doi.org/10.1038/nn.2572
50. Corson P. W.; Nopoulos P.; Miller D. D.; Arndt S.; Andreasen N. C. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am. J. Psychiatry, 1999, 156(8), 1200-4.
51. Andreasen, N. C.; Nopoulos, P.; Magnotta, V.; Pierson, R.; Ziebell, S.; Ho, B. C. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry, 2011, 70(7), 672-9. http://dx.doi.org/10.1016/ j.biopsych.2011.05.017
52. Glenthoj, A.; Glenthoj, B. Y.; Mackeprang, T.; Pagsberg, A. K.; Hemmingsen R. P.; Jernigan T. L.; Baare W. F. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res., 2007, 154(3), 199-208. http://dx.doi.org/10.1016/j.pscychresns.2006.10.002
53. Bellani, M.; Dusi, N.; Brambilla, P. Longitudinal imaging studies in schizophrenia: the relationship between brain morphology and outcome measures. Epidemiol. Psychiatry Soc., 2010, 19(3), 207-10.
54. Garver, D. L.; Holcomb, J. A.; Christensen, J. D. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol. Psychiatry, 2005, 58(1), 62-6. http://dx.doi.org/10.1016/j. biopsych.2005.02.008
55. Hulshoff Pol, H. E.; Hoek, H. W.; Susser, E.; Brown, A. S.; Dingemans, A.; Schnack, H. G.; van Haren, N. E.; Pereira, R.L. M.; Gispen-de Wied C. C.; Kahn R. S. Prenatal exposure to famine and brain morphology in schizophrenia. Am. J. Psychiatry, 2000, 157(7), 1170-2. http://dx.doi.org/10.1176/appi.ajp.157.7.1170
56. Lieberman, J. A.; Tollefson, G. D.; Charles, C.; Zipursky, R.; Sharma, T.; Kahn, R. S.; Keefe, R. S.; Green, A. I.; Gur, R. E.; McEvoy, J.; Perkins, D.; Hamer, R. M.; Gu, H.; Tohen, M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry, 2005, 62(4), 361-70. http://dx. doi.org/10.1001/archpsyc.62.4.361
57. Diamond, G.; Siqueland, L. Current status of family intervention science. Child Adolesc. Psychiatr. Clin. N. Am., 2001, 10(3), 641-61.
58. McCormick, L.; Decker, L.; Nopoulos, P.; Ho, B. C.; Andreasen, N. Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr. Res., 2005, 80(1), 73-84. http://dx.doi.org/10.1016/j.schres.2005.06.022
59. Rais, M.; Cahn, W.; Van Haren, N.; Schnack, H.; Caspers, E.; Hulshoff Pol, H.; Kahn, R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry, 2008, 165(4), 490-6. http://dx.doi.org/10.1176/appi.ajp. 2007.07071110
60. Van Haren, N. E.; Koolschijn, P. C.; Cahn, W.; Schnack, H. G.; Hulshoff Pol, H. E.; Kahn, R. S. Cigarette smoking and progressive brain volume loss in schizophrenia. Eur. Neuropsychopharmacol., 2010, 20(7), 454-8. http://dx.doi.org/10.1016/j.euroneuro.2010. 02.009
61. Crespo-Facorro, B.; Roiz-Santianez, R.; Perez-Iglesias, R.; Pelayo-Teran, J. M.; Rodriguez-Sanchez, J. M.; Tordesillas-Gutierrez, D.; Ramirez, M.; Martinez, O.; Gutierrez, A.; de Lucas, E. M.; Vazquez-Barquero, J. L. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(8), 1936-43. http://dx.doi.org/10.1016/j. pnpbp.2008.09.020
62. Smith, M. J.; Wang, L.; Cronenwett, W.; Goldman, M. B.; Mamah, D.; Barch, D. M.; Csernansky, J. G. Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia. Schizophr. Res., 2011, 131(1-3), 174-83. http://dx. doi.org/10.1016/j.schres.2011.05.014
63. Roiz-Santianez, R.; Tordesillas-Gutierrez, D.; Ortiz-Garcia de la Foz, V.; Ayesa-Arriola, R.; Gutierrez, A.; Tabares-Seisdedos R.; Vazquez-Barquero J. L.; Crespo-Facorro, B. Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Schizophr, Res, 2012, 141(1), 22-8. http://dx.doi.org/10.1016/ j.schres.2012.07.014
64. Pajonk, F. G.; Wobrock, T.; Gruber, O.; Scherk H.; Berner, D.; Kaizl, I.; Kierer, A.; Muller, S.; Oest, M.; Meyer, T.; Backens M.; Schneider-Axmann T.; Thornton, A. E.; Honer, W. G.; Falkai, P. Hippocampal plasticity in response to exercise in schizophrenia. Arch. Gen, Psychiatry, 2010, 67(2), 133-43. http://dx.doi.org/10. 1001/archgenpsychiatry.2009.193
65. Scheepers, F. E.; de Wied, C. C.; Hulshoff Pol, H. E.; van de Flier W.; van der Linden J. A.; Kahn R. S. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology, 2001, 24(1), 47-54. http://dx.doi.org/10.1016/S0893-133X(00) 00172-X
66. Falkai, P.; Malchow, B.; Wobrock, T.; Gruber, O.; Schmitt, A.; Honer, W. G.; Pajonk, F. G.; Sun, F.; Cannon, T. D. The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study. Eur. Arch. Psychiatry Clin. Neurosci., 2013, 263(6), 469-73. http://dx.doi.org/ 10.1007/s00406-012-0383-y
67. Lang, D. J.; Kopala, L. C.; Vandorpe, R. A.; Rui, Q.; Smith, G. N.; Goghari, V. M.; Lapointe, J. S.; Honer, W. G. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am. J. Psychiatry, 2004, 161(10), 1829-36. http://dx.doi.org/10.1176/appi.ajp.161.10.1829
68. Chakos, M. H.; Lieberman, J. A.; Alvir, J.; Bilder, R.; Ashtari, M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet, 1995, 345(8947), 456-7. http://dx.doi.org/10.1016/S0140-6736(95)90441-7
69. Jovicich, J.; Czanner, S.; Han X.; Salat, D.; van der Kouwe, A.; Quinn, B.; Pacheco, J.; Albert, M.; Killiany, R.; Blacker, D.; Maguire, P.; Rosas, D.; Makris N.; Gollub, R.; Dale, A.; Dickerson, B. C.; Fischl, B. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage, 2009, 46(1), 177-92. http://dx.doi.org/10.1016/j.neuroimage.2009.02.010
70. Walters, R. J.; Fox, N. C.; Crum, W. R.; Taube, D.; Thomas, D. J. Haemodialysis and cerebral oedema. Nephron, 2001, 87(2), 143-7. http://dx.doi.org/10.1159/000045903
71. van Haren, N. E.; Hulshoff Pol, H. E.; Schnack, H. G.; Cahn, W.; Mandl, R. C.; Collins, D. L.; Evans, A. C.; Kahn, R. S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology, 2007, 32(10), 2057-66. http://dx.doi.org/10.1038/sj.npp.1301347
72. Jovicich, J.; Czanner, S.; Greve, D.; Haley, E.; van der Kouwe, A.; Gollub, R.; Kennedy, D.; Schmitt, F.; Brown, G.; Macfall, J.; Fischl, B.; Dale, A. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage, 2006, 30(2), 436-43. http://dx.doi.org/10.1016/j. neuroimage.2005.09.046
73. Tomelleri, L.; Jogia, J.; Perlini, C.; Bellani, M.; Ferro, A.; Rambaldelli, G.; Tansella, M.; Frangou, S.; Brambilla, P. Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia. Eur. Neuropsychopharmacol., 2009, 19(12), 835-40. http://dx.doi.org/10.1016/j.euroneuro.2009.07.007
74. Zampieri, E.; Bellani, M.; Crespo-Facorro, B.; Brambilla, P. Basal ganglia anatomy and schizophrenia: the role of antipsychotic treatment. Epidemiol. Psychiatr. Sci., 2014, 23(4), 333-6. http:// dx.doi.org/10.1017/S204579601400064X
75. Senjem, M. L.; Gunter, J. L.; Shiung, M. M.; Petersen, R. C.; Jack C. R., Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage, 2005, 26(2), 600-8. http://dx.doi.org/10.1016/j. neuroimage.2005.02.005
76. Hutcheson, N. L.; Clark, D. G.; Bolding, M. S.; White, D. M.; Lahti, A. C. Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry Res., 2014, 221(1), 6-12. http://dx.doi.org/10.1016/j.pscychresns.2013.10.002
77. Gronenschild, E. H.; Habets, P.; Jacobs, H. I.; Mengelers, R.; Rozendaal, N.; van Os, J.; Marcelis, M. The effects of FreeSurfer version, workstation type, and Macintosh operating system version on anatomical volume and cortical thickness measurements. PLoS One, 2012, 7(6), e38234. http://dx.doi.org/10.1371/journal.pone. 0038234
78. Han, X.; Jovicich, J.; Salat, D.; van der Kouwe, A.; Quinn,B.; Czanner, S.; Busa, E.; Pacheco, J.; Albert, M.; Killiany, R.; Maguire, P.; Rosas, D.; Makris, N.; Dale, A.; Dickerson, B.; Fischl, B. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage, 2006, 32(1), 180-94. http://dx.doi.org/ 10.1016/j.neuroimage.2006.02.051
79. Vernon, A. C.; Crum, W. R.; Lerch, J. P.; Chege, W.; Natesan, S.; Modo, M.; Cooper, J. D.; Williams, S. C.; Kapur,S. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry, 2014, 75(12), 982-90. http://dx.doi.org/10.1016/j.biopsych.2013.09.012